title: Endomicroscopic Imaging of COX-2 Activity in Murine Sporadic and Colitis-Associated Colorectal Cancer.
abstract: Although several studies propose a chemopreventive effect of aspirin for colorectal cancer (CRC) development, the general use of aspirin cannot be recommended due to its adverse side effects. As the protective effect of aspirin has been associated with an increased expression of COX-2, molecular imaging of COX-2, for instance, during confocal endomicroscopy could enable the identification of patients who would possibly benefit from aspirin treatment. In this pilot trial, we used a COX-2-specific fluorescent probe for detection of colitis-associated and sporadic CRC in mice using confocal microscopy. Following the injection of the COX-2 probe into tumor-bearing APCmin mice or mice exposed to the AOM + DSS model of colitis-associated cancer, the tumor-specific upregulation of COX-2 could be validated with in vivo fluorescence imaging. Subsequent confocal imaging of tumor tissue showed an increased number of COX-2 expressing cells when compared to the normal mucosa of healthy controls. COX-2-expression was detectable with subcellular resolution in tumor cells and infiltrating stroma cells. These findings pose a proof of concept and suggest the use of CLE for the detection of COX-2 expression during colorectal cancer surveillance endoscopy. This could improve early detection and stratification of chemoprevention in patients with CRC.
authors: Department of Medicine 1, University of Erlangen-Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany.
authors: Sebastian
authors: S
authors: Foersch
authors: Clemens
authors: C
authors: Neufert
authors: Markus F
authors: MF
authors: Neurath
authors: Maximilian J
authors: MJ
authors: Waldner
references: Eur J Gastroenterol Hepatol. 2004 Jun;16(6):619-25
references: 15167166
references: J Natl Cancer Inst. 2012 Aug 22;104(16):1199-200
references: 22888142
references: Lancet. 2011 Jan 1;377(9759):31-41
references: 21144578
references: Gastroenterology. 1994 Oct;107(4):1183-8
references: 7926468
references: Gastroenterology. 1996 Oct;111(4):1134-40
references: 8831610
references: Cancer Res. 2010 May 1;70(9):3618-27
references: 20430759
references: Cancer Lett. 2009 Jul 8;279(2):221-9
references: 19268443
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: N Engl J Med. 2000 Jun 29;342(26):1960-8
references: 10874065
references: Nat Protoc. 2007;2(8):1998-2004
references: 17703211
references: N Engl J Med. 2003 Mar 6;348(10):891-9
references: 12621133
references: N Engl J Med. 2007 May 24;356(21):2195-8
references: 17522404
references: N Engl J Med. 2007 May 24;356(21):2131-42
references: 17522398
references: Gut. 2010 Aug;59(8):1046-55
references: 20639250
references: Gastroenterology. 2010 Aug;139(2):388-92, 392.e1-2
references: 20561523
references: Gastroenterology. 2004 Aug;127(2):422-7
references: 15300574
references: Lancet Oncol. 2009 May;10(5):501-7
references: 19410194
references: Pathol Res Pract. 2005;201(6):427-33
references: 16136748
references: Am J Physiol Gastrointest Liver Physiol. 2010 Jun;298(6):G797-806
references: 20185688
references: Immunotherapy. 2012 Apr;4(4):397-405
references: 22512634
references: Clin Cancer Res. 2006 Mar 15;12(6):1686-92
references: 16551850
references: Br J Cancer. 2012 Apr 24;106(9):1564-70
references: 22454078
references: Gastroenterology. 2010 Mar;138(3):828-33.e1
references: 20096697
references: Gastroenterology. 2010 Feb;138(2):435-46
references: 19852961